Asked by: Perran Moon (Labour - Camborne and Redruth)
Question to the Department for Education:
To ask the Secretary of State for Education, to what extent young people with long-term health conditions such as epilepsy have been included in the Department’s co-creation process for the forthcoming Schools White Paper.
Answered by Georgia Gould - Minister of State (Education)
The government understands the impact of epilepsy and other long-term medical conditions on the way pupils feel included and supported in school life. The statutory guidance ‘Supporting pupils at school with medical conditions’ recommends the use of individual healthcare plans as good practice. They can help schools support pupils with medical conditions, providing clarity about what needs to be done, when and by whom. The school, healthcare professionals and parents should agree, based on evidence, when a healthcare plan would be appropriate. The government has committed to reviewing the statutory guidance, and we intend to consult on revised guidance. The current guidance is available at: https://www.gov.uk/government/publications/supporting-pupils-at-school-with-medical-conditions--3.
Our aim is to ensure that schools are better equipped to support all pupils with medical conditions, including those with epilepsy, as part of our wider ambition to create more inclusive schools through the forthcoming Schools White Paper.
Asked by: Perran Moon (Labour - Camborne and Redruth)
Question to the Department for Education:
To ask the Secretary of State for Education, what assessment she has made of the role of Individual Healthcare Plans in supporting the safety and inclusion of pupils with long-term health conditions, such as epilepsy, at school.
Answered by Georgia Gould - Minister of State (Education)
The government understands the impact of epilepsy and other long-term medical conditions on the way pupils feel included and supported in school life. The statutory guidance ‘Supporting pupils at school with medical conditions’ recommends the use of individual healthcare plans as good practice. They can help schools support pupils with medical conditions, providing clarity about what needs to be done, when and by whom. The school, healthcare professionals and parents should agree, based on evidence, when a healthcare plan would be appropriate. The government has committed to reviewing the statutory guidance, and we intend to consult on revised guidance. The current guidance is available at: https://www.gov.uk/government/publications/supporting-pupils-at-school-with-medical-conditions--3.
Our aim is to ensure that schools are better equipped to support all pupils with medical conditions, including those with epilepsy, as part of our wider ambition to create more inclusive schools through the forthcoming Schools White Paper.
Asked by: Suella Braverman (Reform UK - Fareham and Waterlooville)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of levels of epilepsy medication availability on patient safety.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Medicine supply issues are global in their nature and, whilst not wholly preventable, the Department has a range of well-established processes and tools to manage and mitigate risks to patients. The Department has worked hard with industry to help resolve intermittent supply issues with some epilepsy medications. As a result of ongoing activity and intensive work, including asking manufacturers to expedite deliveries, most issues have been resolved.
The Department is currently aware of supply issues affecting some suppliers of clobazam 10 milligram tablets, all strengths of topiramate tablets, clonazepam 2 milligram tablets, and phenobarbital 15 milligram tablets, used in the management of epilepsy.
The supply issue with clonazepam 2mg tablets from one manufacturer is expected to resolve late January 2026. The affected suppliers of topiramate 25 milligram and 50 milligram tablets, and clobazam 10 milligram tablets, are expected to resupply these products by early December 2025. The resupply date from the other affected manufacturers for topiramate 50 milligram, 100 milligram and 200 milligram tablets and phenobarbital 15 milligram tablets is yet to be confirmed. Stock remains available from alternative manufacturers of these products to meet patient demand, and we have issued comprehensive management guidance to the National Health Service.
We have issued guidance for the discontinuation of sodium valproate (Epilim Chronosphere) 750 milligram and 1000 milligram modified release (MR) granules sachets. Alternative strengths of sodium valproate MR granules sachets remain available.
Asked by: Peter Dowd (Labour - Bootle)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support and fund clinical trials aimed at achieving licensing and NHS access for complex, cannabis-based medicines used in the treatment of severe, drug-resistant epilepsy in children.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is funding two trials to investigate the safety and efficacy of cannabinoid treatments for drug-resistant epilepsy in both adults and children. Further detail on the trials can be found on the NIHR’s website, at the following link:
https://fundingawards.nihr.ac.uk/award/NIHR131309
The Department is committed to ensuring that all patients, including those with epilepsy, have access to cutting-edge clinical trials and innovative, lifesaving treatments. We are working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of the medicines and therapies of the future, including treatments for epilepsy.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many children with drug-resistant epilepsy have been prescribed cannabis-based medicinal products through private prescriptions in each of the last three years; and what assessment his Department has made of trends in the level of access to cannabis-based medicinal products for children with severe epilepsy unable to afford private prescriptions.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Business Services Authority does not hold the information in the form requested. National Health Service or private controlled drug prescription forms to do contain information on the condition being treated, or why a medicine has been prescribed.
No assessment has been made of trends in the level of access to cannabis-based medicinal products for children with severe epilepsy unable to afford private prescriptions.
The Department does not make provision for the funding of medicines outside of the NHS’ commissioning systems and it remains that the cost of treatments sought privately are the responsibility of patients.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support clinical trials for multi-compound cannabis-based medicinal products for the treatment of drug-resistant epilepsy in children.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is funding two trials to investigate the safety and efficacy of cannabinoid treatments for drug-resistant epilepsy in both adults and children. Further detail on the trials can be found on the NIHR’s website, at the following link:
https://fundingawards.nihr.ac.uk/award/NIHR131309
The Department is committed to ensuring that all patients, including those with epilepsy, have access to cutting-edge clinical trials and innovative, lifesaving treatments. We are working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of the medicines and therapies of the future, including treatments for epilepsy.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what plans her Department has to (a) make alternative forms of identification available as proof of age for venues and (b) work with industry partners to ensure acceptance of other forms of identification as age verification for people unable to obtain a driving license due to epilepsy or other health conditions.
Answered by Ian Murray - Minister of State (Department for Science, Innovation and Technology)
The government has developed a set of requirements (under UK Digital Identity and Attributes Trust Framework (UK DIATF)) for the creation and use of trusted digital verification services, underpinned by the Data (Use and Access) Act 2025. While use of these services is not mandated, it provides an alternative way of proving age for different use cases, including venues.
The Home Office intends to bring forward legislation to enable the use of digital identities as proof of age for purchasing alcohol in England and Wales. This will provide individuals, should they choose, with the option to use a secure digital identity that meets Government standards as an alternative to physical identification. These standards, in the UK DIATF, facilitate private sector providers to use a range of credentials as evidence to create digital identities.
Inclusion is one of the key principles in the UK DIATF, and we work closely with partners in the digital verification services industry on this issue. Digital identities, created through high-quality digital verification services, can be created from a range of documents and datasets, which means proving your age should not be reliant on individuals having a particular credential, like a driving licence.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the annual cost to the NHS of treating children with drug-resistant epilepsy who do not respond to conventional medications; and whether his Department is funding research of alternative treatments to ensure those children still receive sufficient medical care.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
No estimate has been made of the annual cost to the National Health Service of treating children with drug-resistant epilepsy who do not respond to conventional medications. A detailed costing exercise is only usually undertaken where there is a new evidence-based treatment to potentially introduce.
At the national level, there are a number of initiatives supporting service improvement and better care for patients with epilepsy, including the RightCare Epilepsy Toolkit and the Getting It Right First Time Programme for Neurology.
The Department funds research into epilepsy via the National Institute for Health and Care Research (NIHR). The NIHR has funded a range of ongoing and completed epilepsy research, including research into the effectiveness of vagus nerve stimulation as an alternative treatment for children and adults living with drug-resistant epilepsy, and research on implementing ketogenic diet therapy for children and young people with epilepsy.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including alternative treatments for children with drug-resistant epilepsy. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Martin Wrigley (Liberal Democrat - Newton Abbot)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of increasing the availability of medicinal cannabis for epilepsy patients in Devon.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The licenced cannabis-based medicine Epidyolex is available on the National Health Service in England for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This follows approval from the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence (NICE).
NICE has assessed the available evidence, and concluded that there is a clear need for more evidence to support routine prescribing and funding decisions of unlicensed cannabis-based products for medicinal use. NHS funding decisions follow established procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.
Asked by: Suella Braverman (Reform UK - Fareham and Waterlooville)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve public (a) awareness and (b) education on (i) epilepsy and (ii) Sudden Unexpected Death in Epilepsy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
National Institute for Health and Care Excellence (NICE) guidance on epilepsy recommends that clinicians should discuss the risk of Sudden Unexpected Death in Epilepsy (SUDEP) with patients newly diagnosed with epilepsy, and ensure their understanding of the risk, which will raise awareness of the issue among patients and their families.
Additionally, the Royal College of General Practitioners aims to raise awareness of SUDEP amongst GPs and other primary care professionals, through its e-learning modules on SUDEP and seizure safety, which were developed in collaboration with SUDEP Action and last updated in December 2024.
Health Education England, now part of NHS England, has also developed an Epilepsy Programme in collaboration with SUDEP Action, which is designed to enable healthcare professionals, particularly those who are not specialists in epilepsy, to better understand SUDEP and how the risk of SUDEP can be reduced.